@ARTICLE{
author={Davies Andrew J,Mihaljevic Biljana S,Mercadal Santiago,Mihaylov Georgi,Leppa Sirpa,Cotting Denise,Veenstra Klaas,Zharkov Artem,Dixon Mark,Barrett Martin,Macdonald David},
year={2016},
title={Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study},
journal={BLOOD},
volume={128},
number={22},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Davies Andrew J,Merli Francesco,Mihaljevic Biljana S,Siritanaratkul Noppadol,Solal-Celigny Philippe,Boehnke Axel,Berge Claude,McIntyre Christine,Barrett Martin,Macdonald David},
year={2012},
title={Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)},
journal={BLOOD},
volume={120},
number={21},
pages={-},
document_type={Meeting Abstract},
}